OBJECTIVE: To identify differentially expressed genes in peripheral blood mononuclear cells (PBMCs) from patients with ankylosing spondylitis (AS) compared with healthy individuals. METHODS: RNA was extracted from PBMCs collected from 18 patients with active disease and 18 gender-matched and age-matched controls. Expression profiles of these cells were determined using microarray. Candidate genes with differential expressions were confirmed in the same samples using quantitative reverse transcription-PCR (qRT-PCR). These genes were then validated in a different sample cohort of 35 patients with AS and 18 controls by qRT-PCR. RESULTS: Microarray analysis identified 452 genes detected with 485 probes which were differentially expressed between patients with AS and controls. Underexpression of NR4A2, tumour necrosis factor AIP3 (TNFAIP3) and CD69 was confirmed. These genes were further validated in a different sample group in which the patients with AS had a wider range of disease activity. Predictive algorithms were also developed from the expression data using receiver-operating characteristic curves, which demonstrated that the three candidate genes have approximately 80% power to predict AS according to their expression levels. CONCLUSIONS: The findings show differences in global gene expression patterns between patients with AS and controls, suggesting an immunosuppressive phenotype in the patients. Furthermore, downregulated expression of three immune-related genes was confirmed. These candidate genes were also shown to be strong predictive markers for AS.
OBJECTIVE: To identify differentially expressed genes in peripheral blood mononuclear cells (PBMCs) from patients with ankylosing spondylitis (AS) compared with healthy individuals. METHODS: RNA was extracted from PBMCs collected from 18 patients with active disease and 18 gender-matched and age-matched controls. Expression profiles of these cells were determined using microarray. Candidate genes with differential expressions were confirmed in the same samples using quantitative reverse transcription-PCR (qRT-PCR). These genes were then validated in a different sample cohort of 35 patients with AS and 18 controls by qRT-PCR. RESULTS: Microarray analysis identified 452 genes detected with 485 probes which were differentially expressed between patients with AS and controls. Underexpression of NR4A2, tumour necrosis factor AIP3 (TNFAIP3) and CD69 was confirmed. These genes were further validated in a different sample group in which the patients with AS had a wider range of disease activity. Predictive algorithms were also developed from the expression data using receiver-operating characteristic curves, which demonstrated that the three candidate genes have approximately 80% power to predict AS according to their expression levels. CONCLUSIONS: The findings show differences in global gene expression patterns between patients with AS and controls, suggesting an immunosuppressive phenotype in the patients. Furthermore, downregulated expression of three immune-related genes was confirmed. These candidate genes were also shown to be strong predictive markers for AS.
Authors: M Yang; Y Zhou; L Liu; S Wang; J Jiang; Q Shang; H Yu; X Xiang; X Pang; T Li; P Zhao Journal: Clin Exp Immunol Date: 2019-06-30 Impact factor: 4.330
Authors: X B Wang; J J Ellis; D J Pennisi; X Song; J Batra; K Hollis; L A Bradbury; Z Li; T J Kenna; M A Brown Journal: Genes Immun Date: 2017-08-24 Impact factor: 2.676
Authors: Shervin Assassi; John D Reveille; Frank C Arnett; Michael H Weisman; Michael M Ward; Sandeep K Agarwal; Pravitt Gourh; Jiten Bhula; Roozbeh Sharif; Keeran Sampat; Maureen D Mayes; Filemon K Tan Journal: J Rheumatol Date: 2010-10-15 Impact factor: 4.666
Authors: Katelin R Haynes; Allison R Pettit; Ran Duan; Hsu-Wen Tseng; Tibor T Glant; Matthew A Brown; Gethin P Thomas Journal: Arthritis Res Ther Date: 2012-11-22 Impact factor: 5.156